Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism.
Miguel Cosenza-ContrerasAgnes SchäferJustin Cyril SingLena CookMaren N StillgerChia-Yi ChenJose Villacorta HidalgoNiko PinterLarissa MeyerTilman WernerDarleen BugZeno HaberlOliver KübeckKai ZhaoSusanne SteiAnca Violeta GafencuRadu IonitaFelix M BreharJaime Ferrer-LozanoGloria RibasLeo Cerdá-AlberichLuis Martí-BonmatíChristopher NimskyAlexis Van StraatenMartin L BiniossekMelanie FöllNina Cabezas-WallscheidJörg BüscherHannes RöstArmelle ArnouxJörg W BartschOliver SchillingPublished in: Neuro-oncology (2023)
We describe the potential importance of ASAH1 in tumor progression and development of rGBM via metabolic rearrangement and showcase the feedback from the tumor microenvironment to plasma proteome profiles. We report the potential of ASAH1 and SYNM as plasma markers of rGBM progression. The published datasets can be considered as a resource for further functional and biomarker studies involving additional -omics technologies.